Navigation Links
Clarient Generates 52% Revenue Increase in Third Quarter 2007
Date:10/30/2007

ds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company's ability to continue to develop and expand its diagnostic services business, the Company's ability to expand and maintain a successful sales and marketing organization, the Company's ability to maintain compliance with financial and other covenants under its credit facilities, the Company's ability to successfully complete a joint development agreement with Zeiss for the development of novel diagnostic tests, whether the conditions to payment of all or any portion of the contingent consideration from the Company's sale of its instrument systems business are satisfied, the continuation of favorable third party payer reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all , unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, the Company's ability to obtain additional financing if required on favorable terms or
'/>"/>

SOURCE Clarient, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Kylie generates awareness about mammography
2. Health Insurance Scheme Generates Conflicting Opinions
3. Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients
4. Body generates Antibiotic against Urinary Tract Infection
5. Soy Protein Study Generates New Findings
6. Dairy Farmers, Cheesed Off Over Revenue Loss from WIC Program
7. Use of Cellular Phones associated with Increased risk of Brain Tumors
8. Mortality increased in Sporting enthusiasts!
9. Tattoos may significantly increase risk of hepatitis C infection
10. Increase in sugar...decrease in brain function!!!
11. Increase in tobacco deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...mmune response after antiretroviral therapy may be... 25 (HealthDay News) -- A new study challenges the... impairs the immune system,s ability to restore it...tive antiretroviral therapy (HAART). , From 50 ...re also infected with HCV. Intravenous drug use is...
(Date:7/25/2008)..., July 25 /PRNewswire/ -- BeaconEquity.com announc...ng news today., Investors can view all of the dai...conEquity.com/m , Today,s Trade Alerts include: D...rook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMe... ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis In...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ios Spanos was shocked when his doctor discovered ... his body’s largest blood vessel, the aorta, durin...o symptoms, and was relieved to find out that the ...had been caught while it was still small. For the...
... A brewery in Japan launched production of unusual...farmer who was looking for ways to put his milk su...k will be available in the store shelves Thursday,...akashibetsu, on the country's northernmost island ...
... are planning to whiten your teeth by bleaching th...it done by unqualified people could cause consider...alons are offering teeth whitening by unqualified ...l bleach," said Christopher Orr, president of the ...
...tors and nurses who work in the developing world w...challenges, according to ‘Meeting the Health needs... The BMA’s International Committee surveyed 79 UK...including 67 doctors, who had recently worked in A...
Other Medicine News:Health News:Early Detection of Artery Weakening Can Be a Life-Saver 2Health News:Early Detection of Artery Weakening Can Be a Life-Saver 3Health News:Health Workers Need Better Preparation for Developing World 2
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)... Regimens Including Lantus(R) and Apidra(R) Result...ith Type 2 Diabetes, Whatever the Algorithm ...., July 22 /- Results from the "Adjus...mple Algorithm to Carbohydrate,Counting for Adjust...blished in the American Diabetes Association,s (AD...
(Date:7/22/2008)...eveloped and Validated by Columbia University Medi...oprietary MicroRNA Technology, The Test Differen...ung Cancer (NSCLC), Classifying Squamous-Cell Car...ercent and Specificity of 90 Percent,This is the F... Sensitivity as Biomarkers for Accurate D...
(Date:7/22/2008)...lot Study Suggests That Ekkyo,s New Approach of LA...ly Improve Scar Healing Physiology, MARSEILLES, F...wn as,Heatwave Technology) a photomedicine company...s for skin scar prevention and reduction, announce... Lasers in Surgery and Medicine*,reporting the res...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Avantium and BP Extend Strategic Partnership 3782 1Avantium and BP Extend Strategic Partnership 3782 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 1ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 1Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 2
... Useful in Cancer Treatment,Decisions , SALT LAKE ...ASDAQ: MYGN) (<a target="_blank" href=,"http://www...t,it presented studies for a new technology that m... a metastatic tumor, on Monday,April 16, 2007 at ... Cancer Research (AACR) in Los Angeles, California...
...r 19, 2007 - Antares Pharma, Inc.,(AMEX: AIS) anno...ite application study demonstrating that ANTUROL(R...sorbed on a bioequivalent,basis after a single-dos...ns., The study was an open-label, comparative thre...study. The trial enrolled 25,healthy subjects (80%...
Other Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
...y Biotech Captia™ Varicella- Zoster Virus (VZV...s intended for the detection and quantitative dete...dividual serum specimens may be used for the deter...convalescent, may be used to demonstrate seroconve...
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as
The Trinity Biotech Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the qualitative detection of IgM antibody in human serum to Mumps for the determination of immunological experi
The DIAGNOSTIC AUTOMATION, INC. (DAI) Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection and quantitative determination of IgG antibody to Mumps virus in human sera. In
Medicine Products: